GRAVITAS-119, NCT03320642: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease |
|
|
| Terminated | 1 | 84 | Europe, US | Itacitinib, INCB039110, Calcineurin inhibitor | Incyte Corporation | Hematologic Malignancies | 02/21 | 02/22 | | |
haplo-HCT, NCT03755414: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation |
|
|
| Completed | 1 | 55 | US | Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), Human Activity Profile | Washington University School of Medicine, Incyte Corporation, American Society of Hematology, National Cancer Institute (NCI) | Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Disease | 04/24 | 05/24 | | |
